Navigation Links
Updated Financial Standings, Company Announcements, and Customer-Centered Suggestions - Research Report on Perrigo, Thermo Fisher, DaVita, United Therapeutics, and Keryx Biopharmaceuticals
Date:12/20/2013

NEW YORK, December 20, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Perrigo Co. (NYSE: PRGO), Thermo Fisher Scientific, Inc. (NYSE: TMO), DaVita, Inc. (NYSE: DVA), United Therapeutics Corporation (NASDAQ: UTHR), and Keryx Biopharmaceuticals Inc. (NASDAQ: KERX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Perrigo Co. Research Report

On December 17, 2013, Perrigo Co.'s (Perrigo) stock increased 1.46%, ending the day at $153.25. Over the previous three trading sessions, shares of Perrigo declined 0.28%, compared to the Dow Jones Industrial Average which increased 0.86% during the same period. The Full Research Report on Perrigo Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/4168_PRGO

Thermo Fisher Scientific, Inc. Research Report

On December 17, 2013, Thermo Fisher Scientific, Inc.'s (Thermo Fisher) stock increased 0.08%, ending the day at $102.32. Over the previous three trading sessions, shares of Thermo Fisher increased 2.09%, compared to the Dow Jones Industrial Average which also increased 0.86% during the same period. The Full Research Report on Thermo Fisher Scientific, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/45ed_TMO

DaVita, Inc. Research Report

On December 17, 2013, DaVita, Inc. (DaVita) reported that it is dedicated to giving useful tips on winter travel, holiday cooking recipes, and dialysis-friendly gifts. DaVita stated that it encourages patients traveling this holiday season to make and follow a travel checklist - taking note of coordinating with their care team, looking for a convenient dialysis center in the area to which they are traveling (even as a Plan B for those on home modality options), and taking along extra medication and medical information. Patients with wheelchairs or those taking their dialysis equipment along should allow extra time at the airport. Dyane Shanahan, franchisee business owner and DaVita dialysis patient, commented, "Traveling can be stressful, especially during the holidays, but also allows freedom and a chance to return to normalcy for the holidays. As a part-time travel agent, I've been fortunate to travel nationally and internationally and it helps me get back a part of my life before dialysis." Duane Dunn, Director of social work services at DaVita, added, "Patients spend hours on dialysis, whether that is in-center three times a week or at home, so receiving gifts that make their lives easier or help pass the time while they're on dialysis is definitely appreciated. Patients also are often cold, so warm clothing or blankets could be greatly beneficial in making them as comfortable as possible during their treatments." The Full Research Report on DaVita, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/5986_DVA

United Therapeutics Corporation Research Report

On December 17, 2013, United Therapeutics Corporation's (United Therapeutics) stock declined 2.88%, ending the day at $85.89. Over the previous three trading sessions, shares of United Therapeutics declined 5.25%, compared to the Nasdaq Composite which increased 0.63% during the same period. The Full Research Report on United Therapeutics Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/e4cc_UTHR

Keryx Biopharmaceuticals Inc. Research Report

On December 17, 2013, Keryx Biopharmaceuticals Inc.'s (Keryx Biopharmaceuticals) stock declined 0.32%, ending the day at $12.46. Over the previous three trading sessions, shares of Keryx Biopharmaceuticals increased 1.88%, compared to the Nasdaq Composite which also increased 0.63% during the same period.

The Full Research Report on Keryx Biopharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/27d2_KERX

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsCorner.com


'/>"/>
SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
2. Updated: LHA Life Sciences & Medical Technologies Virtual Conference
3. Hoggan Scientific Unveils Updated ergoFET Force Gauge for Improved Force Evaluation
4. Updated HHS Mandate Continues Attack on Religious Freedom
5. Hill-Rom Reports Fiscal Second Quarter Adjusted Earnings Per Share In Line With Expectations; Provides Third Quarter And Updated Full-Year Financial Outlook
6. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
7. TPI Corporate Presentation Updated Regarding Macrolide API Market
8. Pharmacy Technician Certification Board To Introduce Updated Certification Exam On November 1
9. Global Cardiac Medical Devices 2009-2015 - Updated Report
10. Updated: Harwood Feffer LLP Announces Investigation of Edwards Lifesciences Corporation
11. Volcano Corporation Announces Third Quarter 2013 Revenues, Updated Revenue Guidance For Full Year 2013 And Preliminary Revenue Guidance For 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Dec. 6, 2016 Anaplastic Oligoastrocytoma - ... Markets Direct,s latest Pharmaceutical and Healthcare disease pipeline ... provides an overview of the Anaplastic Oligoastrocytoma (Oncology) ... tumor that forms when two types of cells ... increase in number to form a mass. These ...
(Date:12/6/2016)... 2016  Nearly 30 million people in ... of diabetes. 1 However, nearly 40% of diabetes ... (hyperglycemia) and significant glucose variability. 2 These patients are ... events. If left untreated, hyperglycemia can lead to cardiovascular ... blindness. 3 As part of Diabetes ...
(Date:12/6/2016)... 2016  Arcturus Therapeutics, Inc. ("Arcturus" or the ... that it entered into collaboration with Takeda Pharmaceutical ... treatment of NASH and other gastrointestinal (GI) related ... and UNA Oligomer chemistry. The financial terms were ... to and expertise in GI disorders, we are ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... 07, 2016 , ... They are musicians and librarians, fashion designers and fitness ... from New England and around the nation. What do they have in common? All ... a beautiful and compelling new photographic exhibit debuting Friday, December 9 at Logan International ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... and financial consultation services to residents in the Sacramento/Folsom region, is initiating a ... treatment facility. , The Another Choice Another Chance treatment center in Sacramento works ...
(Date:12/7/2016)... ... ... A. Kevin Spann Insurance, a New York-based firm offering insurance and financial consultation ... drive to raise funds that will benefit the Marine Corps League. , The Marine ... Corpsmen. Working closely with the MCL, the A. Kevin Spann team plans to generate ...
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. John D. Rachel ... a portion of proceeds to two local organizations: North Chicago Animal Control and Friends ... is a team of authorized and trained volunteers who support rescued animals held ...
(Date:12/7/2016)... ... 2016 , ... The medical profession is well aware that heart attacks do ... analyzing heart attacks among 138,602 people recorded a 35% higher number of heart attacks ... agree of course–no time of year is a good time for a heart attack! ...
Breaking Medicine News(10 mins):